Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.65 +0.9%	$25.90	$22.64 ▼ $53.96	$1.17B	0.78	474,617 shs	751,553 shs
ETNB 89bio	$7.82 +1.9%	$7.28	$4.16 ▼ $11.84	$1.14B	1.23	1.36 million shs	1.05 million shs
OCUL Ocular Therapeutix	$7.45 +5.6%	$7.45	$4.79 ▼ $11.78	$1.19B	1.51	1.42 million shs	1.69 million shs
RNAC Cartesian Therapeutics	$10.42 +2.7%	$13.24	$8.85 ▼ $41.87	$270.26M	0.51	115,142 shs	69,457 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+2.43%	+0.08%	-2.28%	-25.50%	-42.88%
ETNB 89bio	-1.46%	-4.78%	+39.11%	-33.18%	-18.50%
OCUL Ocular Therapeutix	-1.81%	-15.06%	+11.90%	-7.72%	+18.89%
RNAC Cartesian Therapeutics	-3.97%	-15.42%	+0.40%	-46.04%	-56.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.5036 of 5 stars	3.2	3.0	3.7	3.1	4.2	1.3
ETNB 89bio	2.9968 of 5 stars	4.5	1.0	0.0	4.0	0.8	0.6
OCUL Ocular Therapeutix	3.3926 of 5 stars	3.4	1.0	4.1	2.4	1.7	0.0
RNAC Cartesian Therapeutics	1.7833 of 5 stars	3.4	0.0	0.0	2.8	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.33	Hold	$33.50	35.90% Upside
ETNB 89bio	3.00	Buy	$27.25	248.69% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	118.21% Upside
RNAC Cartesian Therapeutics	2.75	Moderate Buy	$42.50	307.87% Upside

Current Analyst Ratings Breakdown

Latest RNAC, ETNB, OCUL, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/30/2025	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/8/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.60	$3.44 per share	7.17	$13.35 per share	1.85
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
OCUL Ocular Therapeutix	$59.65M	19.89	N/A	N/A	$0.79 per share	9.43
RNAC Cartesian Therapeutics	$38.91M	6.95	N/A	N/A	($82.38) per share	-0.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	8.22	7.49	2.19	21.80%	26.44%	11.89%	N/A
ETNB 89bio	-$142.19M	-$3.38	N/A	N/A	N/A	N/A	-59.58%	-52.21%	5/8/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	N/A
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	5/8/2025 (Estimated)

Latest RNAC, ETNB, OCUL, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
5/1/2025	Q1 2025	ETNB 89bio	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A
3/6/2025	Q4 2024	ETNB 89bio	-$0.60	-$1.02	-$0.42	-$1.02	N/A	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
ETNB 89bio	0.09	11.66	11.66
OCUL Ocular Therapeutix	0.19	13.01	12.94
RNAC Cartesian Therapeutics	N/A	10.70	10.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ETNB 89bio	N/A
OCUL Ocular Therapeutix	59.21%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
ETNB 89bio	2.80%
OCUL Ocular Therapeutix	3.50%
RNAC Cartesian Therapeutics	57.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
ETNB 89bio	40	145.98 million	103.15 million	Optionable
OCUL Ocular Therapeutix	230	159.29 million	151.71 million	Optionable
RNAC Cartesian Therapeutics	64	25.94 million	10.70 million	Optionable

RNAC, ETNB, OCUL, and AMPH Headlines

Recent News About These Companies

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8 at 7:00 AM | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5 at 8:07 AM | insidermonkey.com

683 Capital Management LLC Has $2.24 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)

May 4, 2025 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Price Target at $42.67

April 30, 2025 | americanbankingnews.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLC

April 29, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 27, 2025 | marketbeat.com

Cartesian Therapeutics management to meet with BTIG

April 26, 2025 | markets.businessinsider.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%

April 22, 2025 | aaii.com

JPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)

April 21, 2025 | marketbeat.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%

April 15, 2025 | aaii.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 21.84%

April 15, 2025 | aaii.com

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC)

April 11, 2025 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC)

April 11, 2025 | marketbeat.com

1RNAC : Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In...

April 9, 2025 | benzinga.com

BCMA prospect scores in Cartesian MG phase IIb

April 9, 2025 | bioworld.com

Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III

April 9, 2025 | thepharmaletter.com

Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)

April 9, 2025 | markets.businessinsider.com

Cartesian’s CAR-T may help autoimmune patients long term

April 8, 2025 | statnews.com

Cartesian Therapeutics Shares Rise on Positive Phase 2b Trial Results

April 8, 2025 | marketwatch.com

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, ETNB, OCUL, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.65 +0.22 (+0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$24.65 0.00 (0.00%)

As of 05:55 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

89bio NASDAQ:ETNB

$7.82 +0.15 (+1.89%)

Closing price 03:59 PM Eastern

Extended Trading

$7.51 -0.31 (-3.90%)

As of 07:01 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$7.45 +0.40 (+5.63%)

Closing price 03:59 PM Eastern

Extended Trading

$7.45 +0.00 (+0.04%)

As of 06:58 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$10.42 +0.27 (+2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$10.42 0.00 (0.00%)

As of 05:49 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time